ライフサイエンスコーパス: emetogenic

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 level was determined by identifying the most emetogenic agent in the combination and then assessing t

2 mbination by one level greater than the most emetogenic agent in the combination; and (3) adding leve

3 titration of sedatives, en route to avoiding emetogenic and hyperalgesic volatile anesthetics.

4 ross multiple cycles of moderately or highly emetogenic chemotherapies.

5 nagement problem after treatment with highly emetogenic chemotherapy (HEC).

6 ind, parallel-group study, patients naive to emetogenic chemotherapy (N = 1,085) who were scheduled t

7 r, who had not received moderately or highly emetogenic chemotherapy before, with a Karnofsky perform

8 ptor, about 50% of patients given moderately emetogenic chemotherapy have delayed nausea.

9 omiting associated with moderately or highly emetogenic chemotherapy in adults, but its efficacy and

10 Highly emetogenic chemotherapy induces emesis in almost all pat

11 sk period after administration of moderately emetogenic chemotherapy or regimens containing an anthra

12 th cancer after administration of moderately emetogenic chemotherapy or regimens containing an anthra

13 All patients who receive highly emetogenic chemotherapy regimens (including anthracyclin

14 ecutive administrations of moderately/highly emetogenic chemotherapy were assessed for errors.

15 duled to receive either moderately or highly emetogenic chemotherapy were randomly assigned with an i

16 7% of participants given moderate and highly emetogenic chemotherapy, respectively.

17 inical trials with patients receiving highly emetogenic chemotherapy, the neurokinin antagonist aprep

18 ents receiving taxanes as part of moderately emetogenic chemotherapy, who received dexamethasone acco

19 ter administration of cisplatin-based highly emetogenic chemotherapy.

20 about 1-2 h before administration of highly emetogenic chemotherapy.

21 corticosteroid in patients receiving highly emetogenic chemotherapy.

22 ents being treated with moderately or highly emetogenic chemotherapy.

23 ea and vomiting in patients receiving highly emetogenic chemotherapy.

24 erapy-naive patients who received moderately emetogenic chemotherapy.

25 untreated patients who were receiving highly emetogenic chemotherapy.

26 25-120 h (delayed phase) after initiation of emetogenic chemotherapy.

27 p) 1-2 h before administration of moderately emetogenic chemotherapy.

28 on against CINV in patients receiving highly emetogenic cisplatin-based chemotherapy.

29 eriod (120 h) after administration of highly emetogenic cisplatin-based chemotherapy.

30 tron (32 mg) in patients who received highly emetogenic, cisplatin-based chemotherapy.

31 (1) level 1 agents do not contribute to the emetogenic level of a combination; (2) adding > or = one

32 For combinations, the emetogenic level was determined by identifying the most

33 assigned chemotherapy agents to one of five emetogenic levels by consensus.

34 s were challenged intraperitoneally with the emetogenic NK agonist GR73632 at different doses, and vo

35 provides a practical means to determine the emetogenic potential of individual chemotherapy agents a

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。